lutetium Lu-177 girentuximab

{
  "id": "MLC-T-ONC-014938",
  "term": "lutetium Lu-177 girentuximab",
  "field": "Oncology and biomedicine",
  "definition": "A radioimmunoconjugate consisting of the chimeric monoclonal antibody cG250 linked to the low energy beta-emitting radioisotope Lutetium 177, via the bifunctional macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), with potential antineoplastic activity. The antibody moiety of lutetium Lu-177-DOTA-chimeric monoclonal antibody cG250 binds to renal cell carcinoma (RCC) cells expressing the RCC-associated antigen G250; a cytotoxic dose of beta radiation is selectively delivered to G250-expressing RCC cells upon internalization of the radioimmunoconjugate.",
  "abbreviation": "177Lu-DOTA-cG250",
  "synonyms": [
    "lutetium Lu-177-DOTA-chimeric monoclonal antibody cG250",
    "lutetium-177 labeled cG250"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/lutetium-lu-177-girentuximab/"
}